1 Assessing COVID-19 vaccination strategies
2 in varied demographics using an individual-based model
3 Noam Ben-Zuk1,2, Yair Daon1,2, Amit Sasson3, Dror Ben-Adi1,2,3, Amit Huppert1,4, Daniel 5 Nevo3, Uri Obolski1,2,*
6 1School of Public Health, Tel Aviv University, Tel Aviv, Israel.
7 2Porter School of the Environment and Earth Sciences, Tel Aviv University, Tel Aviv, Israel.
8 3Department of Statistics and Operations Research, Tel Aviv University, Tel Aviv, Israel.
9 4The Bio-statistical and Bio-mathematical Unit, The Gertner Institute for Epidemiology and 10 Health Policy Research, Tel Hashomer, Israel.
33 - SARS-CoV-2
34 - WHO
35 - COVID-19
36 - NPIs
37 - December 2019
38 - Wuhan, China
39 - January 2020
40 - home isolation
41 - workplaces
42 - schools
43 - kindergartens
44 - Food and Drug Administration (FDA)
45 - SARS-CoV-2 vaccine
46 - 4.6 billion people
47 - 11.8 billion doses
48 - different vaccination strategies
49 - rollout rates
50 - prioritization of sub-groups
51 - age
52 - comorbidities
53 - essential workers
54 - Israel
55 - 69%
56 - 81%
57 - new variants
58 - SARS-CoV-2
59 - Delta variant
60 - India
61 - April 2021
62 - Food and Drug Administration (FDA)
63 - two doses
64 - waning vaccine immunity
65 - third dose
66 - mathematical models
67 - compartmental models
68 - SEIR
69 - differential equation-based
70 - Susceptible
71 - Exposed
72 - Infected - Recovered/ Removed
1. Demographics: Each individual in the simulated synthetic population is assigned a certain age, neighborhood, and household. 
2. Infection dynamics: Daily contact between individuals in the described social setting is simulated (29). 
3. Disease states (figure 1): At any given time-point, each individual is classified into one of 
None
109 - Each susceptible individual
110 - Latent period (E to IP/Is; in days)
111 - Duration of preclinical infectiousness
112 - Disease progression and immunity states
113 - Contacts between different age groups and settings
114 - Infectiousness probability
115 - Duration distribution in each state
116 - Susceptibility to infection on contact
117 - Relative infectiousness of subclinical cases
118 - Illustration of the IBM framework
119 - Synthetic population
120 - Hierarchy of social circles
121 - Contact matrices
122 - Orange rectangles represent exposed and infectious states
123 - Purple rectangles represent removed states
124 - Transition rates between the states
125 - Simulation parameters
126 - Table 1
127 - Table S1
None
70% (40) 
Reduction in contacts due to social distancing contacts increase (41) by 25%
Workplace contacts reduce by 25%
Within neighborhood contacts reduce by 25%
Vaccine efficacy (VE) of 90% in preventing infections and hospitalizations (37-39)
Minimum vaccination age (set at 18)
N randomly chosen individuals (who meet the criteria for vaccination)
157 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
158 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
159 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
160 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
161 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
162 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
163 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
164 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
165 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
166 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
167 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
168 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
169 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
170 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
171 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
172 - Neighborhood strategy - each day, the neighborhood (defined as housing approximately
197 simulations.
198 These metrics.
199 150 days.
200 95% confidence intervals.
201 Figure 2.
202 The left- and right-hand columns.
203 500 simulations.
204 The mean differences.
205 Central limit theorem.
206 95% confidence intervals.
207 Results.
208 Figure 2.
209 The cumulative number of new infections per 100k.
210 Hospitalizations per 100k.
211 Rt.
212 Figure 2.
213 The left- and right-hand columns.
214 500 simulations.
215 The shaded regions.
216 Neighborhood vaccination strategies.
217 High transmission rates.
218 Neighborhood Descending strategy.
219 Simulating Holon’s demographics.
220 Neighborhood Descending strategy.
221 Lowest number of infections.
222 General Descending strategy.
223 1.6-fold infections.
224 Bnei Brak.
225 Neighborhood Descending strategy.
226 Reasonable trade-off.
227 Total infections.
228 Total hospitalizations.
229 Both cities.
None
figure 2 e to f: 235
figure S5, S6: 236
figure 3: 237
95% CI [-74.3, -21.9]: 238
95% CI [-64.5, -10.7]: 239
95% CI [-221.3, -162.3]: 240
95% CI [-35.6, 14.6]: 241
95% CI [5.3, 14.3]: 242
95% CI [-13.6, -4.0]: 243
95% CI [-78.8, -66.5]: 244
95% CI [-70.5, -57.5]: 245
95% CI [-508.8, -167.1]: 246
95% CI [-975.3, -625.6]: 247
95% CI [-498.4, -158.8]: 248
95% CI [-964.9, -617.4]: 249
None
-9.3, 95% CI [-185.6, 167.0] for the difference between the Neighborhood Ascending and the Neighborhood Descending strategies 
-93.4, 95% CI [-109.5, -77.3] for the difference between the Neighborhood Descending and Neighborhood Ascending strategies 
-619.25, 95% CI [-641.1, -597.4] for the difference between the General strategies 
73.6, 95% CI [64.5, 82.8] for the difference between the Neighborhood Descending and the General Descending strategy 
-13.3, 95% CI [-31.3, 4.6] for the difference between the Neighborhood Ascending and the General Ascending strategies 
-333.9, 95% CI [-363.2, -304.5] for the difference between the Neighborhood Ascending and the General Descending strategies 
-238.9, 95% CI [-270.6, -207.2] for the difference between the Neighborhood Descending and the General Descending strategies 
-56.0, 95% CI [-66.2, -45.8] for the difference between the Neighborhood Descending and the
336 - interventions and vaccination strategies
337 - selected population structures
338 - number of infections
339 - Rt values
340 - NPIs
341 - Asymptomatic Detection
342 - Household Isolation
343 - younger individuals
344 - more mobile
345 - more contacts per day
346 - secondary infections
347 - less prone to present symptoms
348 - NPIs targeting symptomatic cases
349 - actively testing to detect asymptomatic infections
350 - compliance from parents
351 - use of testing kits
352 - number of infections
353 - hospitalizations
354 - Neighborhood strategies
355 - order of vaccination
356 - single neighborhood
357 - shift from prioritized age group
358 - General Descending strategy
359 - most used vaccination strategy
360 - total hospitalizations
361 - infections
362 - Neighborhood Descending strategy
363 - General Descending strategy
364 - reducing hospitalizations
365 - worst at reducing infections
366 - trade-off between total hospitalizations
367 - infections
368 - Neighborhood Descending strategy
369 - alternative
370 - good trade-off
371 - total hospitalizations
372 - infections
373 - General Descending strategy
None
50 - infection rates
51 - Ebola outbreak in Chow in South Kivu
52 - mass and ring vaccination
53 - side effects
54 - discriminated against
37 - SARS-CoV-2 variants
38 - SARS-CoV-2 variants
39 - SARS-CoV-2 variants
1. World Health Organization. Origin of SARS-CoV-2. 2020 Mar 26;
2. Daon Y, Thompson RN, Obolski U. Estimating COVID-19 outbreak risk through air travel. J Travel Med. 2020 Aug 20;27(5):taaa093.
3. Perra N. Non-pharmaceutical interventions during the COVID-19 pandemic: A review. Phys Rep. 2021 May 23;913:1–52.
4. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, Macdonald B, Beltekian D, Roser M. Coronavirus pandemic (COVID-19). Our world in data. 2020 Mar 5. Our World Data. 2020 Mar 5;
5. Rosen B, Waitzberg R, Israeli A. Israel’s rapid rollout of vaccinations for COVID-19. Isr J Health Policy Res.
447 Science. 2021 Nov 19;374(6570):995–9.
448 10. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021 Dec 9;385(24):e85.
450 11. Gavish N, Yaari R, Huppert A, Katriel G. Population-level implications of the Israeli booster campaign to curtail COVID-19 resurgence. Sci Transl Med. 0(0):eabn9836.
452 12. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. The Lancet. 2021 Dec 4;398(10316):2093–100.
455 13. Feng A, Obolski U, Stone L, He D. Modelling COVID-19 Vaccine Breakthrough Infections in Highly Vaccinated Israel – the effects of waning immunity
25. Aleta A, Martín-Corral D, Pastore y Piontti A, Ajelli M, Litvinova M, Chinazzi M, et al. Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19. Nat Hum Behav. 2020 Sep;4(9):964–71.
26. Català M, Li X, Prats C, Prieto-Alhambra D. The impact of prioritisation and dosing intervals on the effects of COVID-19 vaccination in Europe: an agent-based cohort model. Sci Rep. 2021 Dec;11(1):18812.
27. Davies NG, Klepac P, Liu Y, Prem K, Jit M, CMMID COVID-19 working group, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020 Aug;26(8):1205–11.
28. Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, et al. Demographic science aids in understanding the spread and fatality rates of COVID-19. Proc
38. Katz MA, Harlev EB, Chazan B, Chowers M, Greenberg D, Peretz A, et al. Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI). Vaccine. 2022 Jan 24;40(3):512– 20.
39. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021 Apr 15;384(15):1412–23.
40. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med. 2020 Aug 18;173(4):262–7.
41. Ferguson N, Laydon D, Nedjati Gilani G, Imai N, Ainslie K, Baguelin M,
567 strategies and deployment plans in the EU/EEA.
21 April 2022.
568 Vaccine. 2019 Nov;37(48):7190–200.
569 World Health Organization. Second Ebola vaccine to complement “ring vaccination” given 570 green light in DRC.
571 Merler S, Ajelli M, Fumanelli L, Parlamento S, Piontti AP y, Dean NE, et al. Containing 572 Ebola at the Source with Ring Vaccination.
573 Bullock J, Lane JE, Shults FL. What causes COVID-19 vaccine hesitancy? Ignorance and 574 the lack of bliss in the United Kingdom.
54 Willis DE, Andersen JA, Bryant-Moore K, Selig JP, Long CR, Felix HC, et al. COVID-19 vaccine hesitancy: Race/ethnicity, trust, and fear.
54 Willis DE, Andersen JA, Bryant-Moore K, Selig JP, Long CR, Felix HC, et al. COVID-19
None
